Tocagen Names Lori Kunkel To Board
This article was originally published in Scrip
Executive Summary
Tocagen Inc., a clinical-stage immuno-oncology company, has appointed Lori Kunkel to its board of directors. With more than 20 years' experience in oncology and immunology drug development, Kunkel is currently on the board of Loxo Oncology. Prior to this, she was chief medical officer of Pharmacyclics (acquired by AbbVie) and Proteolix Inc (acquired by Onyx Pharmaceuticals). She was also vice-president of clinical development at Xencor, Inc.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.